Veracyte Announces that Nine Studies Reinforcing the Value of Decipher Prostate and Decipher Bladder Testing Will Be Presented at AUA 2024

April 16, 2024

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Apr. 16, 2024-- Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that nine abstracts focused on its Decipher Prostate and Decipher Bladder Genomic Classifiers will be presented at AUA 2024, the annual meeting of the American Urological Association, taking place May 3-6 in San Antonio. Studies to be presented include those that evaluate the clinical utility of the company's Decipher tests in guiding treatment decisions for patients with prostate or bladder cancer. Other presentations will explore new insights into these cancers' underlying biology, which researchers derived through use of Veracyte's whole-transcriptome-based Decipher GRID research tool.

"The data being presented at AUA 2024 expands the extensive clinical evidence supporting our Decipher Prostate and Decipher Bladder tests," said Elai Davicioni, Ph.D., Veracyte's medical director for Urology. "They also highlight Veracyte's commitment to collaborating with leading researchers to help understand the biological underpinnings of urologic cancers and advance the science around the disease areas we serve."

The following abstracts will be presented in the Henry B. González Convention Center:

Title: High Decipher score defines the subgroup most at risk of metastatic progression among patients with lower grade tumors classified as NCCN high-risk based on elevated prostate-specific antigen level alone
Presenter: David Han, M.D., Columbia University Irving Medical Center
Format: Poster (MP41-14)
Date/Time: Saturday, May 4, 2024 / 3:30 p.m. to 5:30 p.m. CT
Room #: 304B

Title: Decipher® Predicts Clinically Significant Upgrading on Final Radical Prostatectomy Pathology
Presenter: John Sheng, M.D., Rutgers New Jersey Medical School
Format: Poster (MP49-09)
Date/Time: Sunday, May 5, 2024 / 7:00 a.m. to 9:00 a.m. CT
Room #: 221B

Title: Genomic Signatures Associated with Adverse Pathologic Features at Radical Prostatectomy Among Active Surveillance Eligible Men
Presenter: Eric Li, M.D., Northwestern University
Format: Poster (MP41-09)
Date/Time: Saturday, May 4, 2024 / 3:30 p.m. to 5:30 p.m. CT
Room #: 304B

Title: Variation in Prostate Cancer Genomic Subtypes Across Prostate Magnetic Resonance Imaging PIRADS Scores and Race
Presenter: Nimrod Barashi Gozal, M.D., Washington University in St. Louis
Format: Podium Presentation (PD42-01)
Date/Time: Sunday, May 5, 2024 / 9:30 a.m. to 9:40 a.m. CT
Room #: 303A

Title: Transcriptomic Features of Clinically Localized Prostate Cancer Arising from Distinct Prostate Zonal Regions
Presenter: Ross Liao, M.D., Cleveland Clinic
Format: Poster (MP41-13)
Date/Time: Saturday, May 4, 2024 / 3:30 p.m. to 5:30 p.m. CT
Room #: 304B

Title: Glucagon-like peptide-1 Expression in Prostate Cancer
Presenter: Mohammed Shahait, M.D., Private Practice
Format: Poster (MP05-10)
Date/Time: Friday, May 3, 2024 / 7:00 a.m. to 9:00 a.m. CT
Room #: 221C

Title: Molecular subtyping for predicting non-organ confined disease and survival outcomes after radical cystectomy in clinical high-grade T1 and T2 bladder cancer patients
Presenter: Yair Lotan, M.D., UT Southwestern Medical Center
Format: Poster (MP15-07)
Date/Time: Friday, May 3, 2024 / 1:00 p.m. to 3:00 p.m. CT
Room #: 221C

Title: The stroma-rich consensus bladder cancer subtype correlates with improved prognosis after neoadjuvant immunotherapy and radical cystectomy

Presenter: Joep De Jong, Ph.D., Erasmus MC, The Netherlands
Format: Podium Presentation (PD14-05)
Date/Time: Friday, May 3, 2024 / 4:10 p.m. to 4:20 p.m. CT
Room #: 301A

Title: A lncRNA-based classifier identifies high grade T1 bladder cancer patients with excellent outcomes after radical cystectomy
Presenter: Yair Lotan, M.D., UT Southwestern Medical Center
Format: Poster (MP15-02)
Date/Time: Friday, May 3, 2024 / 1:00 p.m. to 3:00 p.m. CT
Room #: 221C

Additional information regarding these presentations and Veracyte's participation at AUA 2024 can be found at the company's booth (#607).

About Decipher Prostate

The Decipher Prostate Genomic Classifier is a 22-gene test, developed using RNA whole-transcriptome analysis and machine learning, that helps inform treatment decisions for patients with prostate cancer. The test is performed on biopsy or surgically resected samples and provides an accurate risk of developing metastasis with standard treatment. Armed with this information, the physician can better personalize their patients' care and may recommend less-intensive options for those at lower risk or earlier, more-intensive treatment for those at higher risk of metastasis. The Decipher Prostate test has been validated in more than 75 studies involving more than 100,000 patients. More information about the Decipher Prostate test can be found here.

About Decipher Bladder

The Decipher Bladder Genomic Classifier is a 219-gene test, developed using RNA whole-transcriptome analysis and machine learning, that is designed for use in patients following bladder cancer diagnosis who face questions regarding treatment intensity. The test classifies bladder tumors into five molecular subtypes, each having distinct tumor biology and potential clinical implications. This information can help physicians and their patients better understand the degree of benefit that would likely be gained from neoadjuvant chemotherapy and/or the likelihood of harboring non-organ-confined disease at time of surgery, respectively. More information about the Decipher Bladder test can be found here.

About Decipher GRID

The Decipher GRID database includes more than 200,000 whole-transcriptome profiles from patients with urologic cancers and is used by Veracyte and its partners to contribute to continued research and help advance understanding of prostate and other urologic cancers. GRID-derived information is available on a Research Use Only basis. More Information about Decipher GRID can be found here.

About Veracyte

Veracyte (Nasdaq: VCYT) is a global diagnostics company whose vision is to transform cancer care for patients all over the world. We empower clinicians with the high-value insights they need to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. Our Veracyte Diagnostics Platform delivers high-performing cancer tests that are fueled by broad genomic and clinical data, deep bioinformatic and AI capabilities, and a powerful evidence-generation engine, which ultimately drives durable reimbursement and guideline inclusion for our tests, along with new insights to support continued innovation and pipeline development. For more information, please visit www.veracyte.com and follow the company on X (formerly Twitter) at @veracyte.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements, including, but not limited to our statements related to the potential impact these studies may have on advancing the science around Decipher in prostate and bladder cancer. Forward-looking statements can be identified by words such as: "appears," "anticipate," "intend," "plan," "expect," "believe," "should," "may," "will," "enable," "positioned," "offers," "designed" and similar references to future periods. Actual results may differ materially from those projected or suggested in any forward-looking statements. These statements involve risks and uncertainties, which could cause actual results to differ materially from our predictions, and include, but are not limited to the potential impact Decipher GRID can have on scientific advancements in prostate cancer and, in turn, patients. Additional factors that may impact these forward-looking statements can be found under the caption "Risk Factors" in our Annual Report on Form 10-K filed on March 1, 2024. Copies of these documents, when available, may be found in the Investors section of our website at https://investor.veracyte.com. These forward-looking statements speak only as of the date hereof and, except as required by law, we specifically disclaim any obligation to update these forward-looking statements or reasons why actual results might differ, whether as a result of new information, future events or otherwise. These forward-looking statements speak only as of the date hereof and, except as required by law, we specifically disclaim any obligation to update these forward-looking statements or reasons why actual results might differ, whether as a result of new information, future events or otherwise.

Veracyte, the Veracyte logo, and Decipher are registered trademarks of Veracyte, Inc., and its subsidiaries in the U.S. and selected countries.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240416752482/en/

Investors:
Shayla Gorman
investors@veracyte.com
619-393-1545

Media:
Tracy Morris
media@veracyte.com
650-380-4413

Source: Veracyte, Inc.